🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Assessment of CT-FFR in Patients With CCS: A Prospective Multicenter Cohort Study

Recruitingn/aAges 18 Years - anyAllSecond Affiliated Hospital, Zhejiang University, …
NCT07659119 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The ACCURATE-PRO study is an investigator-initiated, prospective, multicenter, observational, real-world cohort study. The core objective in managing chronic coronary syndrome (CCS) is to identify clinically significant myocardial ischemia to guide treatment decisions and improve long-term prognosis. While coronary computed tomography angiography (CCTA) is a crucial non-invasive anatomical imaging tool, it has limitations in determining the functional significance of coronary stenosis. Computed tomography-derived fractional flow reserve (CT-FFR) provides this functional assessment non-invasively based on CCTA images. However, there is a lack of systematic, prospective, multicenter evidence regarding its clinical value in risk stratification, treatment decision support, and prognostic evaluation for a continuous, real-world spectrum of CCS patients in China. This study aims to evaluate t

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 18 years. * Clinical diagnosis of chronic coronary syndrome (CCS). * Completed coronary computed tomography angiography (CCTA) examination and successfully obtained CT-derived fractional flow reserve (CT-FFR) results. * The subject or their legal representative voluntarily participates in this study and has signed the written informed consent form. Exclusion Criteria: * Acute coronary syndrome (ACS), including ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), or acute episodes of unstable angina. * Unable to obtain valid CT-FFR results, or the image quality is insufficient to support analysis. * Pregnant patients or those who intend to become pregnant during the study period. * Non-cardiac comorbidities indicating a life expectancy of less than one year. * Failure to sign the informed consent form. * Inability to complete the follow-up or explicit refusal to participate in the follow-up. * Patients with cognitive impairment or psychiatric disorders confirmed by clinical diagnosis or investigator assessment. * Patients who are illiterate or semi-literate, or who, due to any visual impairment or reading/writing disability, are unable to independently read the subject information sheet without assistance and are unable to personally provide written informed consent. * Any other conditions deemed unsuitable for participation in this study by the investigators
💊

What it tests

  • Not listed
📍

Where

1 site
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy